Irritable Bowel Syndrome Drugs Market Analysis

Type {IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), Mixed IBS (IBS-M)}

The global irritable bowel syndrome drugs market is segmented and analyzed for demand and supply by type into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and mixed IBS (IBS-M). Out of these, the IBS with diarrhea (IBS-D) segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing prevalence of diarrhea among all age groups and the rising adoption of unhealthy lifestyles including the consumption of fast food and alcohol. For instance, diarrheal illnesses are believed to be responsible for 300 annual pediatric fatalities and 167,000 hospitalizations in the US.

Our in-depth analysis of the global irritable bowel syndrome drugs market includes the following segments:

By Type	IBS with Diarrhea (IBS-D) IBS with Constipation (IBS-C) Mixed IBS (IBS-M)
By Product	Xifaxan Linzess Amitiza Viberzi Others
By End User	Drug Stores & Retail Pharmacies Hospital Pharmacies Online Pharmacies

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of irritable bowel syndrome drugs is estimated at USD 4.43 billion.

The irritable bowel syndrome drugs market size was over USD 4.14 billion in 2024 and is projected to cross USD 11.53 billion by the end of 2037, growing at more than 8.7% CAGR during the forecast period i.e., between 2025-2037. Increasing incidences of irritable bowel syndrome and growing availability of over the counter drugs will impel the market growth.

North American region is anticipated to hold the largest share by 2037, driven by increasing frequency of fecal incontinence and the availability of efficient treatment options in the region.

The major players in the market include Abbott Services, Ardelyx, Inc., Astellas Pharma Inc., AstraZeneca, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Novartis AG, Ironwood Pharmaceuticals, Inc., Synergy Pharma Consultancy Private Limited, Synthetic Biologics, Inc.

Irritable Bowel Syndrome Drugs Market Analysis